Skip Navigation



Annals of Oncology Advance Access published online on October 15, 2007
Annals of Oncology, doi:10.1093/annonc/mdm430
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/1/115    most recent
mdm430v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kosmidis, P. A.
Right arrow Articles by Dimopoulos, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kosmidis, P. A.
Right arrow Articles by Dimopoulos, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group

P. A. Kosmidis1,*, H. P. Kalofonos2, C. Christodoulou3, K. Syrigos4, T. Makatsoris2, D. Skarlos3, C. Bakogiannis1, C. Nicolaides5, D. Bafaloukos6, A. Bamias7, E. Samantas8, N. Xiros9, I. Boukovinas10, G. Fountzilas11 and M. A. Dimopoulos7

1 Department of Medical Oncology, Hygeia Hospital, Athens
2 Division of Oncology, University Hospital of Patras, Patras
3 2nd Department of Medical Oncology, Henry Dunant Hospital, Athens
4 Oncology Unit, 3rd Department of Medicine, Athens Medical School, Sotiria General Hospital, University of Athens, Athens
5 Department of Medical Oncology, University of Ioannina School of Medicine, Ioannina
6 Department of Medical Oncology, Metropolitan Hospital, Piraeus
7 Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens
8 3rd Department of Medical Oncology, Agii Anargiri Cancer Hospital, University of Ioannina, Athens
9 2nd Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital Attikon, Athens
10 Department of Medical Oncology, Theagenio Hospital, University of Athens Thessaloniki
11 Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

* Correspondence to: Dr P. A. Kosmidis, Hygeia Hospital, 2 An Tsoha & Vas Sofias Avenue, Athens 11521, Greece. Tel: +30 21-645-8602; Fax: +30 21-645-2616; E-mail: parkosmi{at}otenet.gr

Background: This phase III study was designed to compare the combination paclitaxel (Taxol)–gemcitabine (PG) versus carboplatin–gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.

Methods: Chemotherapy-naive patients with performance status of zero or one were randomized to gemcitabine 1 gm/m2 on days 1 and 8 plus either paclitaxel 200 mg/m2 on day 1 (arm A) or carboplatin at an area under the concentration–time curve of 6 mg on day 1 (arm B) every 3 weeks. Primary end point was overall survival (OS). Secondary end points included objective response (OR), time to progression and toxicity.

Results: A total of 512 patients were enrolled and 452 eligible (arm A, 225; arm B, 227) were analyzed. All characteristics were well balanced with the exception of vena cava obstruction symptoms and lymph node involvement. Median survival was 9.97 months [95% confidence interval (CI) 8.74–12.0] for group A and 10.49 (95% CI 9.04–11.94) for group B. There was no difference in the OS, 1-year survival, OR and TtP. However, statistically significant differences were seen in toxicity.

Conclusion: The two regimens are equally active. Myelotoxicity is worse in the CG group whereas alopecia, myalgia and neurotoxicity worse in the PG group.

carboplatin, chemotherapy, gemcitabine, non-small-cell lung cancer, paclitaxel

Received for publication May 17, 2007. Revision received July 24, 2007. Accepted for publication July 24, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al.
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
Ann. Onc., October 15, 2009; (2009) mdp352v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. K. Chew, J. H. Doroshow, P. Frankel, K. A. Margolin, G. Somlo, H.-J. Lenz, M. Gordon, W. Zhang, D. Yang, C. Russell, et al.
Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer
J. Clin. Oncol., May 1, 2009; 27(13): 2163 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
A. G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K. D. DILANA, E. M. KARAPANAGIOTOU, and K. N. SYRIGOS
Therapy-induced Toxicity of the Lungs: An Overview
Anticancer Res, February 1, 2009; 29(2): 631 - 639.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.